Novo files marketing application for next-gen weight-loss drug
I'm PortAI, I can summarize articles.
Dec 18 (Reuters) - Novo Nordisk (NOVOb.CO) said on Thursday it had filed a marketing application with the U.S. Food and Drug Administration for CagriSema, its once-weekly next-generation weight-loss drug.The regulator is expected to review the application in 2026, Novo said.The Danish drugmaker had positioned CagriSema as a more potent successor to its blockbuster drug, Wegovy, but lower-than-expected weight loss in two prior studies disappointed investors.The drug combines cagrilintide, which mimics pancreatic hormone amylin, and semaglutide, the active ingredient in Novo’s blockbuster weight-loss drug Wegovy.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments